|
Recent Developments |
|
28-JAN-19
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC today announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA).
16-JAN-19
Dr Reddy's Laboratories announced that audit of the company's Formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh by the USFDA, has been completed on January 15, 2019. The company has been issued a Form 483 with 4 observations.
12-DEC-1... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2016(9) | 31-Mar-2016(12) | 31-Mar-2015 (12) | | Net sales | 73286.00 | 101284.60 | 99274.50 | | Other Income | 5447.00 | 3070.90 | 2228.50 | | Total Income | 78733.00 | 104355.50 | 101503.00 | | Cost of goods sold | 62872.00 | 78660.20 | 76199.40 | | OPBDIT | 15861.00 | 25695.30 | 25303.60 | | PAT | 11611.00 | 13544.70 | 16793.50 | | Gross Block | - | - | - | | Equity capital | 829.00 | 853.00 | 851.90 | | EPS (Rs.) | - | - | 98.60 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | 22.82 - 37.14 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 20.1 | 24.6 | 24.9 | | Net margin (% of OI) | 14.7 | 13.0 | 16.5 |
|
|
Detailed Financials
|
|
|
|
|
